Home › NDC Lookup › Ingredients › Hypromellose 2910 › 00065-0408-72
👁️image loading
(from DailyMed)

Alcon Tears Lubricant Eye Drops hypromellose 2910 2910 (4000 MPA.S) 5 mg/mL Solution/ Drops — NDC 0065-0408-72 (Billing 00065-0408-72)

by Alcon Laboratories, Inc. · 1 BOTTLE, DROPPER in 1 CARTON / 15 mL in 1 BOTTLE, DROPPER

This is a package of Alcon Tears Lubricant Eye Drops hypromellose 2910 2910 (4000 MPA.S) 5 mg/mL Solution/ Drops from Alcon Laboratories, Inc., marketed since Mar 2022 and currently FDA-listed; retail pharmacies pay about $2.10 per mL (NADAC). It is this product's only package size.

NDC 00065-0408-72
🏷️ FDA NDC (as labeled) 0065-0408-72 billing pads the labeler segment with a zero
OTC On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0065-0408-72 alone.

Record
FDA NDC Directory package listing · Human OTC drug
Code segments
0065 labeler · 0408 product · 72 package
Package marketed since
Mar 1, 2022
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC)
0300650408721
Medicaid fills, this package
911 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0065-0408-72
Product NDC 0065-0408
11-digit billing NDC 00065040872
NCPDP billing unit ML — per mL (volume)
RxCUI 142002
UNII RN3152OP35
UPC 0300650408721
Application # M018
SPL Set ID 89302e2b-882b-48d5-8df7-be37859b48ba
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2022-03-01
Route OPHTHALMIC
Dosage form SOLUTION/ DROPS
Substance HYPROMELLOSE 2910 (4000 MPA.S)

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 007932
GCN 33410
HICL code 008840
Ingredient (HICL) Hypromellose
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q6
Therapeutic class — intermediate (HIC2) Ophthalmic Preparations
HIC3 code Q6T
Therapeutic class — specific (HIC3) Artificial Tears
AHFS code 52:92.00.00
AHFS class Eent Drugs, Miscellaneous
FDB label name TEARS LUBRICANT 0.5% EYE DROP
FDB brand name Tears Lubricant Eye Drop
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 007932
  • GCN: 33410
  • HICL (First Databank): 008840
  • AHFS class code: 52:92.00.00
  • RxCUI (RxNorm): 142002
Why two NDCs? The FDA registers this code as 0065-0408-72 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00065-0408-72. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Viscoelastic substances class.

Drug family (ATC) Viscoelastic substances
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name TEARS LUBRICANT 0.5% EYE DROP Ingredient Hypromellose
🧪 What is this product?

This is an over-the-counter eye drop solution containing hypromellose, a lubricating agent commonly used to relieve dryness and irritation of the eye surface. The product is applied directly to the eye as needed to help moisturize and protect the cornea and conjunctiva. Hypromellose functions as an artificial tear substitute, intended to provide temporary comfort and clear vision by supplementing the eye's natural tear film. This product is marketed under the FDA's OTC monograph rules for lubricating eye drops.

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $2.100 $31.49 / 15 ml
Medicaid paysCMS SDUD · 12 mo $2.22 $33.26 / 15 ml
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per mL) — tap or hover for the price & month
Jul 2025 Mar 2026 Jun 2026 Sep 2026 $2.100 $2.029
▲ Up 4% over the last 9 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
00065-0408-72 You're viewing this Main listing 1 BOTTLE, DROPPER in 1 CARTON / 15 mL in 1 BOTTLE, DROPPER 2022-03-01 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Alcon Tears Lubricant Eye Drops 2910 (4000 MPA.S) 5 mg/mLthis 00065-0408-72 Alcon 1 bottle $2.100 — Availability likely —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2022
On the market since
Mar 2022
📍
2026
Currently FDA-listed
4 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerAlcon Laboratories, Inc.
FDA applicationM018 (OTC MONOGRAPH DRUG)
Labeler code00065
First marketedMar 2022
Product typeHuman Otc Drug
Portfolio55 products on file

More NDCs from Alcon Laboratories, Inc. labeler code 00065

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Do Not Use 📄 When Using This Product 📄 Stop Use and Ask a Doctor If 📄 Keep Out of Reach of Children 📄 Other Information 📄 Questions or Comments 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 23 words ▾

Uses for the temporary relief of burning and irritation due to dryness of the eye for use as a protectant against further irritation

⏱️ Dosage and Administration 12 words ▾

Directions instill 1 or 2 drops in the affected eye(s) as needed

⚠️ Warnings 5 words ▾

Warnings For external use only

🧪 Active Ingredient 8 words ▾

Active i ngredients Purpose Hypromellose 2910 0.5% Lubricant

🧪 Inactive Ingredients 19 words ▾

Inactive ingredients benzalkonium chloride 0.01% as preservative, dibasic sodium phosphate, monobasic sodium phosphate, purified water, sodium chloride, sodium citrate

🎯 Purpose 8 words ▾

Active i ngredients Purpose Hypromellose 2910 0.5% Lubricant

📄 Do Not Use 21 words ▾

Do not use if this solution changes color or becomes cloudy if you are sensitive to any ingredient in this product

📄 When Using This Product 26 words ▾

When using this product remove contact lenses before using to avoid contamination, do not touch tip of container to any surface replace cap after each use

📄 Stop Use and Ask a Doctor If 31 words ▾

Stop use and ask a doctor if you experience any of the following: eye pain changes in vision continued redness or irritation condition worsens or persists for more than 72 hours

📄 Keep Out of Reach of Children 19 words ▾

Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

📄 Other Information 6 words ▾

Other information store at room temperature

📄 Questions or Comments 6 words ▾

Questions? In the U.S. call 1-800-757-9195

📄 Package Label / Principal Display Panel 60 words ▾

PRINCIPAL DISPLAY PANEL Alcon Tears LUBRICANT Eye Drops For Relief of Dry Eye Symptoms STERILE 15 mL (1/2 FL OZ) Alcon TAMPER EVIDENT: For your protection, this bottle has an imprinted seal around the neck. Do not use if seal is damaged or missing at time of purchase. Alcon ALCON LABORATORIES, INC. Fort Worth, Texas 76134 USA Printed in USA

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
911
Units reimbursed last 4 qtrs
14.3K
Gross reimbursed last 4 qtrs
$31.7K
Avg / prescription
$34.79
Avg / unit
$2.2173
Latest quarter Q1 2026
184Rx
Medicaid pays / mL
$2.2173
gross reimbursed
vs
NADAC / mL
$2.0996
acquisition cost
=
Spread
+$0.1177
+6% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
38% FFS 62% MCO
Fee-for-service · 347 Rx Managed care · 564 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 3,375 units · 58.8 per 100k residents MN Wisconsin: no data reported WI Michigan: no data reported MI New York: no data reported NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: no data reported OH Pennsylvania: no data reported PA New Jersey: 210 units · 2.3 per 100k residents NJ Massachusetts: no data reported MA California: 5,040 units · 12.9 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: 525 units · 26.5 per 100k residents NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: 5,145 units · 142 per 100k residents CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
2.3142
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Connecticut 142 /100k
2 Minnesota 58.8 /100k
3 Nebraska 26.5 /100k
4 California 12.9 /100k
5 New Jersey 2.3 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.
← 00065-0397-02 · Alcon 00065-0411-30 · Alcon →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.